Skip to main content
SpringerLink
Log in

Clinical response to ruxolitinib in CSF3R T618-mutated chronic neutrophilic leukemia

  • Letter to the Editor
  • Published:
Annals of Hematology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

References

  1. Tefferi A, Vardiman JW (2008) Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia 22(1):14–22. doi:10.1038/sj.leu.2404955

    Article  CAS  PubMed  Google Scholar 

  2. Tefferi A, Elliott M, Pardanani A (2015) Chronic neutrophilic leukemia: novel mutations and their impact on clinical practice. Curr Opin Hematol 22(2):171–176. doi:10.1097/MOH.0000000000000114

    Article  CAS  PubMed  Google Scholar 

  3. Gotlib J, Maxson JE, George TI, Tyner JW (2013) The new genetics of chronic neutrophilic leukemia and atypical CML: implications for diagnosis and treatment. Blood 122(10):1707–1711. doi:10.1182/blood-2013-05-500959

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Maxson JE, Gotlib J, Pollyea DA, Fleischman AG, Agarwal A, Eide CA, Bottomly D, Wilmot B, McWeeney SK, Tognon CE, Pond JB, Collins RH, Goueli B, Oh ST, Deininger MW, Chang BH, Loriaux MM, Druker BJ, Tyner JW (2013) Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML. N Engl J Med 368(19):1781–1790. doi:10.1056/NEJMoa1214514

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Pardanani A, Lasho TL, Laborde RR, Elliott M, Hanson CA, Knudson RA, Ketterling RP, Maxson JE, Tyner JW, Tefferi A (2013) CSF3R T618I is a highly prevalent and specific mutation in chronic neutrophilic leukemia. Leukemia 27(9):1870–1873. doi:10.1038/leu.2013.122

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Dao KH, Solti MB, Maxson JE, Winton EF, Press RD, Druker BJ, Tyner JW (2014) Significant clinical response to JAK1/2 inhibition in a patient with CSF3R-T618I-positive atypical chronic myeloid leukemia. Leukemia Res Rep 3(2):67–69. doi:10.1016/j.lrr.2014.07.002

    Article  Google Scholar 

  7. Lasho TL, Mims A, Elliott MA, Finke C, Pardanani A, Tefferi A (2014) Chronic neutrophilic leukemia with concurrent CSF3R and SETBP1 mutations: single colony clonality studies, in vitro sensitivity to JAK inhibitors and lack of treatment response to ruxolitinib. Leukemia 28(6):1363–1365. doi:10.1038/leu.2014.39

    Article  CAS  PubMed  Google Scholar 

  8. Makishima H, Yoshida K, Nguyen N, Przychodzen B, Sanada M, Okuno Y, Ng KP, Gudmundsson KO, Vishwakarma BA, Jerez A, Gomez-Segui I, Takahashi M, Shiraishi Y, Nagata Y, Guinta K, Mori H, Sekeres MA, Chiba K, Tanaka H, Muramatsu H, Sakaguchi H, Paquette RL, McDevitt MA, Kojima S, Saunthararajah Y, Miyano S, Shih LY, Du Y, Ogawa S, Maciejewski JP (2013) Somatic SETBP1 mutations in myeloid malignancies. Nat Genet 45(8):942–946. doi:10.1038/ng.2696

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Elliott MA, Pardanani A, Hanson CA, Lasho TL, Finke CM, Belachew AA, Tefferi A (2015) ASXL1 mutations are frequent and prognostically detrimental in CSF3R-mutated chronic neutrophilic leukemia. Am J Hematol 90(7):653–656. doi:10.1002/ajh.24031

    Article  CAS  PubMed  Google Scholar 

Download references

Author contributions

Maximilian Stahl contributed in the literature search, figures, study design, data collection, data analysis, data interpretation and writing.

Mina Xu contributed in the figures, study design, data collection, and writing.

David P. Steensma contributed in the data interpretation and writing.

Raajit Rampal contributed in the data interpretation and writing.

Melissa Much contributed in the figures, study design, data collection, and writing.

Amer M Zeidan contributed in the literature search, figures, study design, data collection, data analysis, data interpretation, and writing.

Author information

Authors and Affiliations

  1. Department of Pathology, Brady Memorial Laboratory, Yale School of Medicine, 310 Cedar Street, New Haven, CT, 06510, USA

    Maximilian Stahl, Mina L. Xu, Melissa Much & Amer M Zeidan

  2. Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA, 02215, USA

    David P. Steensma

  3. Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY, 10065, USA

    Raajit Rampal

Authors
  1. Maximilian Stahl
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mina L. Xu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. David P. Steensma
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Raajit Rampal
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Melissa Much
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Amer M Zeidan
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Maximilian Stahl.

Ethics declarations

Conflict of interest

Dr. Steensma and Dr. Rampal consulted for Incyte and received honoraria. All other authors have no relevant conflicts.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Stahl, M., Xu, M.L., Steensma, D.P. et al. Clinical response to ruxolitinib in CSF3R T618-mutated chronic neutrophilic leukemia. Ann Hematol 95, 1197–1200 (2016). https://doi.org/10.1007/s00277-016-2664-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-016-2664-4

Keywords

Search

Navigation